The findings of the PATRICIA study are reported in an article Online First and in a future edition of The Lancet. It shows that the HPV-16/18 AS04-adjuvanted vaccine (GlaxoSmithKline) has high efficacy against the precancerous cervical lesions that can eventually lead to cervical cancer. There is confirmation that the vaccine also shows cross-protective efficacy against other oncogenic (that cause cancer) Human Papillomavirus (HPV) types closely related to HPV-16/18.